Highest-materiality recent filing
Rhythm Pharma Q2 revenue $71.3M; RM-718 shows -11.6% BMI reduction in HO
Q2 2026 IMCIVREE revenue $71.3M, up 19% sequentially; U.S. revenue $51.0M (+38% QoQ).
Rhythm posts positive PWS Phase 2 data; MC4R agonist results at ENDO 2026
Interim Phase 2 PWS: 17 patients; mean BMI -3.06% at 6 months; 8/10 with moderate-severe hyperphagia improved ≥7 on HQ-CT.
Rhythm Q1 product revenue $60.1M; IMCIVREE HO launch >150 start forms; net loss $(0.83)/share
Q1 2026 net product revenue $60.1M (up 5% sequentially); U.S. revenue $36.9M, ex-U.S. $23.2M.
Rhythm Pharma gets positive CHMP opinion to expand IMCIVREE label for acquired hypothalamic obesity
CHMP recommends expanding IMCIVREE (setmelanotide) marketing authorization to treat obesity/control hunger in patients >=4 years with acquired HO due to hypothalamic injury.
FDA approved IMCIVREE (setmelanotide) for acquired HO in adults and children 4+; first approved therapy for this indication.
Rhythm's Phase 3 EMANATE trial misses primary endpoints; post hoc signals in POMC/SRC1
Four substudies failed primary endpoint: placebo-adjusted BMI reductions of 4.3% (POMC/PCSK1), 3.6% (LEPR), 4.0% (SRC1), 1.7% (SH2B1); all p>0.05.
Rhythm reports additional positive Phase 3 TRANSCEND data for setmelanotide in hypothalamic obesity
Placebo-adjusted BMI reduction of 18.8% (N=142); primary endpoint met with -16.4% BMI change on setmelanotide vs +2.4% on placebo (p<0.0001).
Q4 2025 IMCIVREE revenue $57.3M, up 12% sequentially; full year revenue $194.8M vs $130.1M in 2024.
Rhythm Pharma Q4 2025 IMCIVREE revenue ~$57M (+11% QoQ); FY2025 ~$194M (+50% YoY)
Q4 2025 net product revenue ~$57M, up 11% sequentially from Q3 2025.
Rhythm Pharma reports positive Phase 2 setmelanotide data in PWS; plans Phase 3
18 patients enrolled; 17 remain on therapy; safety consistent with known profile.
FDA extends review of Rhythm's setmelanotide sNDA to March 20, 2026
New PDUFA goal date March 20, 2026, extended 3 months from December 20, 2025.
Rhythm Q3 IMCIVREE revenue $51.3M; net loss -$0.82/sh; PDUFA Dec 20
Q3 2025 IMCIVREE revenue $51.3M (+6% seq, +54% YoY); US $38.2M (+19% seq).
Q2 net product revenue $48.5M, up 29% sequentially from Q1 2025; US revenue $32.0M (66% of total), up 31%.
Rhythm Pharmaceuticals raises $188.7M in public equity offering; underwriters exercise full option
Offering of 2,058,824 shares at $85.00 per share; underwriters exercised 30-day option for 308,823 additional shares in full.
Rhythm Pharma's bivamelagon Phase 2 meets endpoints: -9.3% BMI reduction at 14 weeks
BMI reduction -9.3% (600mg, p=0.0004) and -7.7% (400mg, p=0.0002) vs 2.2% increase on placebo.
Rhythm Q1 product rev $37.7M; Phase 3 HO trial meets endpoint with -19.8% BMI reduction
Net product revenue $37.7M, up from $26.0M YoY; U.S. $24.5M, ex-U.S. $13.2M.
Mean BMI change of -16.5% on setmelanotide vs +3.3% for placebo at 52 weeks (p<0.0001); 80% achieved ≥5% BMI reduction.
Rhythm terminates RareStone license for IMCIVREE in China; reacquires rights for $6.3M
Termination of 2021 Exclusive License and Share Purchase agreements with RareStone Group Ltd.
Rhythm Q4 2024 IMCIVREE revenue $41.8M; cash runway extended to 2027
Q4 2024 IMCIVREE net revenue $41.8M (+26% sequential, +73% YoY); FY2024 total $130.1M.
Preliminary Q4 2024 IMCIVREE net revenues of ~$42M, up 26% sequentially; full year ~$130M vs $77.4M in 2023.
Rhythm Pharma Q3 revenue $33.3M (+14% seq); FDA Priority Review for label expansion to age 2
IMCIVREE net revenue $33.3M (Q3 2024), up 48% YoY from $22.5M; US sales $23.3M (+8% seq), ex-US $10.0M (+35% seq).
Rhythm Pharma Q2 2024 revenue $29.1M, up 52% YoY; net loss narrows to $33.6M
Net product revenue $29.1M vs $19.2M in Q2 2023; 74% generated in United States.
Rhythm Pharma Q1 net revenue $26.0M (+126% YoY); net loss $141.4M on $92.4M LB54640 charge
Net product revenue $26.0M (Q1 2023: $11.5M); 74% from U.S. sales.
Rhythm Pharmaceuticals closes $150M Series A Convertible Preferred issuance to Perceptive affiliates
Closed on April 15, 2024; issued 150,000 shares at $1,000 each for aggregate $150,000,000.
Rhythm Pharma raises $150M in convertible preferred stock; conversion at $48 (19% premium)
$150M gross proceeds from sale of Series A Convertible Preferred Stock to Perceptive and other existing shareholders.
Rhythm Pharmaceuticals amends sales agreement to allow up to $200M in at-the-market stock offerings
Amendment increases ATM offering limit from $100M to $200M, excluding $50M already sold.
Rhythm Pharma Q4 IMCIVREE rev $24.2M; reports material weakness in IT controls
Q4 2023 net product revenue $24.2M (FY2023 $77.4M) vs $8.8M Q4 2022; net loss $41.6M ($0.70/share).
Rhythm Pharmaceuticals licenses LB54640 from LG Chem for $60M upfront plus $40M deferred
License deal: $40M cash + $20M stock upfront; additional $40M cash due 18 months after effective date.
Rhythm Pharma reports positive Phase 3 setmelanotide data in young children; files for EU approval
Phase 3 pediatrics trial: 83.3% (10/12) achieved BMI-Z score reduction ≥0.2 at 52 weeks; mean BMI reduction 18.4%.
Rhythm Pharma Q3 IMCIVREE revenue $22.5M, net loss $44.2M; Phase 3 hypothalamic obesity on track
Q3 2023 net product revenue from IMCIVREE $22.5M vs $4.3M in Q3 2022; 80% from U.S.
Rhythm Pharmaceuticals raises $50M via ATM equity offering of 2M shares
Sold ~2.019M shares of common stock from Aug 10-21, 2023, for gross proceeds of ~$50M.
Rhythm Q2 2023 revenue $19.2M; BBS prescriptions top 425; eligible for $25M milestone payment
Q2 2023 net product revenue $19.2M (vs $2.3M Q2 2022); net loss $46.7M ($0.82/share).
Rhythm Pharma Q1 revenue $11.5M, net loss $52.2M; BBS prescriptions over 300 since launch
Net product revenue $11.5M in Q1 2023 vs $1.5M YoY; net loss $52.2M ($0.92/sh) vs $52.8M ($1.05/sh).
Rhythm Pharma Q4 2022 product revenue $8.8M, net loss $42.5M; BBS launch >200 scripts
Product revenue $8.8M Q4 2022, $16.9M FY; net loss $42.5M ($0.75/sh) Q4, $181.1M ($3.47/sh) FY.
Rhythm Q3 2022: IMCIVREE revenue $4.3M; net loss $40.9M; cash $347.8M
Product revenue $4.3M vs $1.0M YoY; net loss $40.9M ($0.79/share) vs $35.1M ($0.70).
On August 8, 2023, the Board of Directors of the Company designated Christopher German, the Company’s Executive Director, Corporate Controller, as principal accounting officer, effective on the Effective Date.
On August 4, 2023, Rhythm Pharmaceuticals, Inc. (the “Company”) notified William T. Roberts, the Company’s Chief Accounting Officer, of the termination of Mr. Roberts’ employment with the Company, to be effective on August 11, 2023
The Board has appointed Linda Shapiro Manning, M.D., Ph.D., currently Senior Vice President, Clinical of the Company, to succeed Dr. Stewart as Chief Medical Officer as of the Effective Date.
On August 31, 2021, Murray Stewart, D.M., F.R.C.P. notified Rhythm Pharmaceuticals, Inc. (the “Company”) of his resignation as Chief Medical Officer, effective as of September 10, 2021
Max materiality 0.90 · Median 0.70 · Most common event other_material